Evidence map›Paper›PMID 40591420›Full record

ArticleThe Journal of clinical investigation2025

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares.

James G Krueger, Mrinal K Sarkar, Mark G Lebwohl, Akimichi Morita, Kenneth Gordon, Rachael Bogle, Christopher Cole, Anthony Coon, Richard G Langley, Richard B Warren and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

James G KruegerLaboratory for Investigative Dermatology, Rockefeller University, New York City, New York, USA.
Mrinal K SarkarUniversity of Michigan, Ann Arbor, Michigan, USA.
Mark G LebwohlIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Akimichi MoritaNagoya City University, Nagoya, Japan.
Kenneth GordonMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Rachael BogleUniversity of Michigan, Ann Arbor, Michigan, USA.
Christopher ColeUniversity of Michigan, Ann Arbor, Michigan, USA.
Anthony CoonUniversity of Michigan, Ann Arbor, Michigan, USA.
Richard G LangleyDalhousie University, Halifax, Nova Scotia, Canada.
Richard B WarrenDermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
Arash MostaghimiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Bruce StroberYale University School of Medicine, New Haven, Connecticut, USA and Central Connecticut Dermatology Research, Cromwell, Connecticut, USA.
A David BurdenSchool of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom.
Min ZhengSchool of Medicine, Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Aaron R MangoldMayo Clinic, Scottsdale, Arizona, USA.
Milan J AnadkatWashington University School of Medicine, St. Louis, Missouri, USA.
Jonathan N BarkerSt. John's Institute of Dermatology, King's College London, London, United Kingdom.
Joseph F MerolaUT Southwestern Medical Center, Dallas, Texas, USA.
Lam C TsoiUniversity of Michigan, Ann Arbor, Michigan, USA.
Ming TangBoehringer Ingelheim (China) Investment Co. Ltd, Shanghai, China.
Kolja BeckerBoehringer Ingelheim International GmbH, Biberach, Germany.
Denis DelicBoehringer Ingelheim International GmbH, Biberach, Germany.
Christian ThomaBoehringer Ingelheim International GmbH, Biberach, Germany.
Johann E GudjonssonDivision of Rheumatology, University of Michigan and Taubman Medical Research Institute, Ann Arbor, Michigan, USA.

Funding

University of Michigan Skin Biology and Diseases Resource-based CenterP30AR075043 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Johann Eli Gudjonsson · 2019 to 2026
$6.6M
NIAMS NIH HHS P30 AR075043
6 · The paper itself

Abstract

People with generalized pustular psoriasis experience underlying skin inflammation, even in the absence of flares. Spesolimab treatment helps control the inflammation and prevent future flares.

Indexed as

Antibodies, Monoclonal, HumanizedPsoriasisReceptors, InterleukinFemaleHumansInflammationMaleMiddle AgedAntibodies, Monoclonal, Humanizedinterleukin-36 receptor, humanReceptors, InterleukinDermatologyInflammationNeutrophilsSkin

Identifiers

PMID40591420
PMCPMC12404765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.